Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The investigators will treat 100 patients with cirrhosis due to hepatitis C with sofosbuvir
400 mg daily, daclatasvir 60 mg daily and weight-based ribavirin (1000 mg/d if <75 kg, 1200
mg/d if >75 kg, divided in two daily doses) for 12 weeks and calculate the sustained viral
response rate at 12 weeks.